Challenges of delivery of dental care and dental pathologies in children and young people with osteogenesis imperfecta
Tóm tắt
Osteogenesis imperfecta (OI) is the most common inherited disorder of bone fragility in children, increasing fracture risk 100-fold and can feature dental and facial bone involvement causing additional morbidities. To assess the utilisation of tertiary dental services by children and young people with OI attending a supra-regional multi-disciplinary OI service and review of the pathology identified and interventions undertaken. Case notes review of the current caseload of children and young people (0–18 years) with OI at a large regional OI specialist centre (n = 92). Primary outcome was whether an initial dental assessment was arranged in a tertiary dental centre and the corresponding attendance. 49% had a tertiary dental assessment arranged, of whom 82% attended (one quarter requiring several appointments) and 18% did not attend (DNA).Those travelling > 100 miles had a DNA rate of 47%. Assessed children had dentinogenesis imperfecta (24%, 50% in Type III OI), radiographs (95%), caries (41%), required extraction under general anaesthesia (38%) and malocclusion (30%). 48% of the total cohort received bisphosphonates. Tertiary dental assessment encountered barriers to uptake of recommended referral in all patients, often due to geographic factors of travel distance, yet when implemented did identify pathology in a large proportion and many resulted in dental intervention. These emphasise the relevance of specialist dental assessment in OI, particularly in the modern context of increased use of bisphosphonates. This is challenging to achieve and several models of delivery of care may need to be considered in this chronic childhood condition.
Tài liệu tham khảo
Abukabbos H, Ali-Sineedi F. Clinical manifestation and dental management of dentinogenesis imperfecta associated with osteogenesis imperfecta. Saudi Dent. J. 2013;25:159–65.
Barron MJ, McDonnell ST, Mackie I, Dixon MJ. Hereditary dentine disorders—dentinogenesis imperfecta and dentine dysplasia. Orphanet J Rare Dis. 2008;31:10–8.
Ben Amor IM, Roughley P, Glorieux FH, Rauch F. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J Bone Miner Res. 2013;28:2001–7.
Bhatt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: review of the literature and guidelines for dental management. Aust Dent J. 2014;59:9–19.
Bradaschia-Correa V, Massa LF, Arana-Chavez VE. Effects of alendronate on tooth eruption and molar root formation in young, growing rats. Cell Tissue Res. 2007;330:475–85.
Christou J, Hodgson TA, Johnson AR. The Dental management of children on bisphosphonates therapy in the UK. Oral Diseas. 2012;18:3–48.
Christou J, Johnson AR, Hodgson TA. Bisphosphonate-related osteonecrosis of the jaws and its relevance to children—a review. Int J Pediatr Dent. 2013;23:330–7.
Engelbert RH, Uiterwaal CS, Gerver WJ, et al. Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with a 4 year follow up. Arch Phys Med Rehabil. 2004;85:772–8.
Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr Opin Pediatr. 2008;20:52–7.
Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387:1657–71.
Iglesias-Linares A, Yanez-Vico RM, Solano-Reina E, Torres-Lagares D, Gonzalez-Moles MA. Influence of bisphosphonates in orthodontic therapy: systematic review. J Dent. 2010;38:603–11.
Imbert L, Auregan JC, Pernelle K, Hoc T. Mechanical and mineral properties of osteogenesis imperfecta human bone at the tissue level. Bone. 2014;65:18–24.
Jensen BL, Lund AM. Osteogenesis imperfecta: clinical, cephalometric, and biochemical investigations of OI types I, III, and IV. J Craniofac Genet Dev Biol. 1997;17:121–32.
Khan AA, Sandor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009;36:478–90.
Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 2008;37:196–200.
Marini JC, Blissett AR. New genes in bone development: what's new in osteogenesis imperfecta. J Clin Endocrinol Metab. 2013;98:3095
O’Connell AC, Marini JC. Evaluation of Oral Problems in Osteogenesis Imperfecta. J Oral Surg Oral Med Oral Path Oral Rad Oral Endo. 1999;87:189–96.
Okawa R, Kubota T, Kitaoka T, et al. Oral manifestations of Japanese patients with osteogenesis imperfecta. Paediatr Dental J. 2017;27:73–8.
Patel RM, Nagamani SC, Cuthbertson D, et al. A cross sectional multi-centred study of osteogenesis imperfecta in North America. Clin Genet. 2015;87:133–40.
Rizkallah J, Schwartz S, Rauch F, et al. Evaluation of the severity of malocclusion in children affected by osteogenesis imperfecta with the peer assessment rating and discrepancy index. Am J Orthod Dentofac Orthop. 2012;143:336–41.
Rosen A, Modig M, Larson O. Orthognathic bimaxillary surgery in two patients with osteogenesis imperfecta and a review of the literature. Int J Oral Maxillofac Surg. 2011;40:866–86.
Sapir S, Shapira J. Clinical solutions for developmental defects of enamel and dentine in children. Pediatr Dent. 2007;29:330–6.
Shields ED, Bixler D, El-Kafrawy AM. A proposed classification for heritable human dentine defects with a description of a new entity. Arch Oral Biol. 1973;18:543–53.
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–16.
Teixeira CS, Santos-Felippe MCS, Tadeu-Felippe WT. The role of dentists in diagnosing osteogenesis imperfecta in patients with dentinogenesis imperfecta. J Am Dent Assoc. 2008;139:906–14.
Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents—new developments in diagnosis and treatment. Osteoporos Int. 2016;27:427–37.
Tsakos G, Hill K, Chadwick B, Anderson T. Children’s dental health survey 2013. Attitudes, behaviours and children’s dental health. England, Wales and Northern Ireland, HSCIC, 2015. 2013
Uday S, Gaston CL, Rogers L, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumour of bone. J Clin Endocrinol Metab. 2018;103:596–603.
Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164:1470–81.
Vuorimies I, Arponen H, Valta H, et al. Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment. Bone. 2017;94:29–33.